RNA binding motif protein 22 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored RBM22P2 profile across patient tissues and cancer cell-line models. RBM22P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RBM22P2 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, RBM22P2 RNA expression shows 16,462 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, BLCA, and UVM as cancer lineages where RBM22P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM22P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM22P2 survival associations across molecular data types. RBM22P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM22P2 RNA expression–survival associations across cancer types. High RBM22P2 expression shows unfavorable associations in KIRC and UVM, but favorable associations in PAAD, SKCM, LUAD and READ. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RBM22P2 RNA expression.
This table summarizes RBM22P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBM22P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM22P2 shows lower tumor expression in BLCA, UCEC, BRCA, KIRP and LUSC and higher tumor expression in LIHC. The BLCA box plot shows higher RBM22P2 RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p = .026).
This table shows molecular features associated with RBM22P2 in patient tissues and cancer cell lines. In patient samples, RBM22P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
